What are ADC's

Our services

ADC Review
is made possible by:

NCT02539719 (Clinical Trial/ SC-003)

Study Title
Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer (NCT02539719)

Trial Description
This is a Phase 1a/1b study of SC-003 in patients with platinum-resistant/refractory ovarian cancer. SC-003 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy.

This trial is sponsored by Stemcentrx®.

Study Data

  • Condition:
    • Ovarian Cancer
  • Interventions:
    • Drugs used in this trial
      • SC-003
  • Phase: I
  • Estimated Enrollment: 108
  • Start: August 2015
  • Estimated Completion: February 2017
  • Last updated: April 2016
  • Last verified: April 2016

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: August 3, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar